头孢地尔罗酯对多重耐药鲍曼不动杆菌的抗菌活性。
Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii.
机构信息
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA.
出版信息
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0264620. doi: 10.1128/AAC.02646-20.
Abstract
Cefiderocol (CFDC), a novel siderophore cephalosporin, demonstrates strong activity against multidrug-resistant (MDR) Acinetobacter baumannii. Limited studies have evaluated CFDC alone and in combination with other Gram-negative antibiotics against MDR A. baumannii isolates. Susceptibility testing revealed lower CFDC MIC values (87% of MICs ≤ 4mg/liter) than the comparator Gram-negative agents. Six isolates, with elevated CFDC MICs (16 to 32 mg/liter) were selected for further experiments. Time-kill analyses presented with synergistic activity and beta-lactamase inhibitors increased CFDC susceptibility in each of the isolates.
摘要
头孢地尔（CFDC）是一种新型的铁载体头孢菌素，对多种耐药（MDR）鲍曼不动杆菌具有很强的活性。有限的研究评估了 CFDC 单独使用以及与其他革兰氏阴性抗生素联合使用对 MDR 鲍曼不动杆菌分离株的作用。药敏试验显示 CFDC 的 MIC 值较低（87%的 MIC 值≤4mg/L），低于比较的革兰氏阴性药物。选择了 6 株 CFDC MIC 值升高（16 至 32mg/L）的分离株进行进一步实验。时间杀伤分析显示协同作用和β-内酰胺酶抑制剂增加了每种分离株对 CFDC 的敏感性。
相似文献
1
Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0264620. doi: 10.1128/AAC.02646-20.
2
Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.
Clin Microbiol Infect. 2024 Feb;30(2):178-188. doi: 10.1016/j.cmi.2023.08.029. Epub 2023 Sep 4.
3
Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
Pharmacotherapy. 2020 Dec;40(12):1228-1247. doi: 10.1002/phar.2476. Epub 2020 Nov 19.
4
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
5
Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0087721. doi: 10.1128/AAC.00877-21. Epub 2021 Jul 12.
6
Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
J Antimicrob Chemother. 2020 Jul 1;75(7):1840-1849. doi: 10.1093/jac/dkaa117.
7
Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan.
J Glob Antimicrob Resist. 2022 Mar;28:120-124. doi: 10.1016/j.jgar.2021.12.017. Epub 2021 Dec 25.
8
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Int J Antimicrob Agents. 2019 Feb;53(2):177-184. doi: 10.1016/j.ijantimicag.2018.10.007. Epub 2018 Oct 26.
9
First detection of a cefiderocol-resistant and extensively drug-resistant Acinetobacter baumannii clinical isolate in Bulgaria.
Acta Microbiol Immunol Hung. 2024 Jan 23;71(1):25-36. doi: 10.1556/030.2024.02201. Print 2024 Mar 26.
10
Structural Basis of PER-1-Mediated Cefiderocol Resistance and Synergistic Inhibition of PER-1 by Cefiderocol in Combination with Avibactam or Durlobactam in Acinetobacter baumannii.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0082822. doi: 10.1128/aac.00828-22. Epub 2022 Nov 15.
引用本文的文献
1
Evaluating Antimicrobial Susceptibility Testing Methods for Cefiderocol: A Review and Expert Opinion on Current Practices and Future Directions.
Antibiotics (Basel). 2025 Jul 28;14(8):760. doi: 10.3390/antibiotics14080760.
2
Innovative perspectives on the discovery of small molecule antibiotics.
NPJ Antimicrob Resist. 2025 Mar 13;3(1):19. doi: 10.1038/s44259-025-00089-0.
3
Successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis and purulent ventriculitis using cefiderocol combination therapy: a case report and literature review.
Eur J Clin Microbiol Infect Dis. 2025 May;44(5):1245-1250. doi: 10.1007/s10096-025-05077-w. Epub 2025 Feb 21.
4
The Evolution of Antimicrobial Resistance in and New Strategies to Fight It.
Antibiotics (Basel). 2025 Jan 14;14(1):85. doi: 10.3390/antibiotics14010085.
5
Microbiome-derived antimicrobial peptides show therapeutic activity against the critically important priority pathogen, Acinetobacter baumannii.
NPJ Biofilms Microbiomes. 2024 Sep 30;10(1):92. doi: 10.1038/s41522-024-00560-2.
6
Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria.
Cells. 2024 Aug 6;13(16):1315. doi: 10.3390/cells13161315.
7
Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant spp.
Microbiol Spectr. 2024 Oct 3;12(10):e0093024. doi: 10.1128/spectrum.00930-24. Epub 2024 Aug 20.
8
Lacticaseibacillus rhamnosus CRL 2244 secreted metabolites display killing and antibiotic synergistic activity against multi-drug resistant pathogens.
PLoS One. 2024 Jun 28;19(6):e0306273. doi: 10.1371/journal.pone.0306273. eCollection 2024.
9
Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant spp.
bioRxiv. 2024 Mar 4:2024.03.04.583376. doi: 10.1101/2024.03.04.583376.
10
Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections.
Microbiol Spectr. 2024 Feb 6;12(2):e0310823. doi: 10.1128/spectrum.03108-23. Epub 2024 Jan 11.
本文引用的文献
1
Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Due to AmpC R2 Loop Deletion.
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00198-20.
2
Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
Trials. 2019 Jun 6;20(1):330. doi: 10.1186/s13063-019-3437-x.
3
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
4
Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study.
Open Forum Infect Dis. 2018 Sep 21;5(10):ofy241. doi: 10.1093/ofid/ofy241. eCollection 2018 Oct.
5
Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01968-17. Print 2018 Feb.
6
Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria.
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01454-17. Print 2018 Jan.
7
Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study).
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00093-17. Print 2017 Sep.
8
Active efflux pump adeB is involved in multidrug resistance of induced by antibacterial agents.
Exp Ther Med. 2017 Apr;13(4):1538-1546. doi: 10.3892/etm.2017.4141. Epub 2017 Feb 21.
9
Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design.
Diagn Microbiol Infect Dis. 2017 Jun;88(2):198-200. doi: 10.1016/j.diagmicrobio.2017.03.011. Epub 2017 Mar 23.
10
Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S30-S35. doi: 10.1093/cid/ciw829.
Zotero 插件